Navigation Links
Biovail Concerned Shareholders Welcome Glass Lewis Evaluation
Date:6/18/2008

Independent Report Sharply Criticizes Current Management

Recommends 'Do Not Vote' For Any of the Company's Nominees

TORONTO, June 18 /PRNewswire/ -- The Concerned Shareholders of Biovail Corporation (NYSE: BVF)(TSX: BVF) said today that they welcomed a report by Glass Lewis & Co., which sharply criticized the incumbent board and recommended 'Do Not Vote' for any of the company's nominees.

Glass Lewis recommended a vote FOR two of the Concerned Shareholders nominees, Joseph J. Krivulka and Laurence W. Zeifman. It recommended withholding votes from the other eight nominees on the Concerned Shareholders' slate.

The Glass Lewis report took issue with several actions by the current board, particularly its executive appointments and compensation packages.

"While the board should be seeking to put its troubled history in the past, it has instead appointed its former CEO as chairman and a former member of an audit committee which oversaw significant restatements as its new CEO," the report says. "We believe that shareholders could benefit from the addition of new independent voices on the board with appropriate subject matter and industry expertise."

The Glass Lewis report called the appointment of Biovail's CEO, William Wells, "a curious choice at best," as well as "inappropriate from a corporate governance perspective." It concludes: "At the very least such an appointment could only further serve to damage the Company's already bruised public image."

Glass Lewis also expressed disapproval of executive compensation arrangements made by the incumbent board. It notes that Mr. Wells chaired the compensation and nominating committees, and that the retiring CEO, Douglas Squires, was awarded a package of $3.5 million, including a retroactive raise, even though the company's share price was falling.

"An outside observer would conclude that these potentially excessive compensation awards for Messrs. Squires and Wells, especially at a time of poor financial performance, may be related to the appointment of Mr. Wells," the report says. "Even if Mr. Wells' past position in overseeing the committee which determines executive pay and identified the new CEO did not affect his appointment as CEO or the generous contracts for him and his predecessor, the mere appearance of corruption could be damaging."

Bruce D. Brydon, CEO of Biovail during some of its most successful years, who will return as CEO if the Concerned Shareholders' slate is elected, said he wants to get the company back on the right track. Mr. Brydon said: "We believe that Biovail needs a complete change in its board, senior management and direction to avoid even further declines in shareholder value."

Mr. Brydon noted that:

-- In the last year the price of Biovail stock has declined nearly 50%, far worse than the drug industry stock price index.

-- In the last four years, under current management, Biovail has obtained regulatory approval for only one new drug, in sharp contrast to the 17 new drugs that were approved during Mr. Brydon's tenure as CEO from 1995 to 2001.

-- A leading financial analyst who covers Biovail and other drug companies has stated that the new strategic direction announced recently by Biovail's current management, to focus intensive research and development on new chemical entities to treat central nervous system conditions such as Alzheimer's Disease, "is just baffling to us."

All shareholders are urged to vote the YELLOW proxy in favour of the Concerned Shareholders slate of nominees. Copies of the proxy circular prepared by the Concerned Shareholders can be obtained via SEDAR (http://www.sedar.com) and http://www.betterbiovail.com or by contacting in Canada, Kingsdale Shareholder Services Inc. toll-free at 1-800-775-1986 or collect at 1-416-867-2272, or in the United States, Innisfree M&A Incorporated toll-free at 1-877-717-3929.

Certain statements contained in this release constitute forward-looking statements. The words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Concerned Shareholders, the Concerned Shareholders' nominees, the Company or its current or future management, are intended to identify forward-looking statements. Such statements reflect the Concerned Shareholders' or the Concerned Shareholders' nominees' current views with respect to future events and are subject to certain risks, uncertainties and assumptions. The Concerned Shareholders' nominees assume no responsibility for any such statements. Many factors could cause the company's actual results, performance or achievements that may be expressed or implied by such forward- looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include, but are not limited to, economic, business, technological, competitive and regulatory factors.


'/>"/>
SOURCE Bruce Brydon
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
2. Biovail Concerned Shareholders Want Open Debate
3. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
6. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
7. Pharmos Issues Letter to Shareholders
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
10. YM Biosciences announces adoption of renewed Shareholders Rights Plan
11. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 2017 , ... Resoundant, Inc. is pleased to introduce ... U.S. that offer MR Elastography for liver fibrosis staging. MR Elastography is ... liver fibrosis assessment. , “MRE:connect was created in response to an increasing number ...
(Date:7/20/2017)... ... July 20, 2017 , ... Litmus Health , a ... full advisory board. The board comprises leaders spanning business, technology, academia, and pharmaceutical ... VP of Engineering, to Chief Technology Officer. Crooks will lead strategy and development ...
(Date:7/20/2017)... ... July 20, 2017 , ... Corista, ... pathology and artificial intelligence Tuesday, July 25, during the Association of Pathology Chairs’ ... Hopkins Medicine. , Baras, Associate Director of Pathology Informatics, will present “The ...
(Date:7/20/2017)... , ... July 20, 2017 , ... Corporate Directors Forum ... its 27th annual Director of the Year Awards. , The awards will be presented ... This annual event celebrates directors who have made significantly positive contributions in the ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):